Adverse kidney events

Disease

1 paper1 finding

Humans1

Associations

SGLT2 inhibitors

downin humans1

1 study

SGLT2 inhibitors lower the risk of adverse kidney events in humans (AHR 0.62 (95% CI, 0.46-0.83); 3.9% vs 6.2%).
Humansrecovering from dialysis-requiring acute kidney injury in type 2 diabetesprescription within 30 days vs 31 to 90 days after dischargemean follow-up of 3.4 years
Early Sodium-Glucose Cotransporter-2 Inhibitor Use After Acute Kidney Injury in Type 2 Diabetes
JAMA network open3 Aug 2026

Latest

12 in 12 months

Drug Design, Development and Therapy4 Oct

Prior Use of GLP-1 Receptor Agonists versus SGLT2 Inhibitors and Clinical Outcomes After Sepsis in Patients with Type 2 Diabetes: A Propensity Score-Matched Cohort Study

Cohort study of 11,969 peopleSepsis

Paper

Journal of Diabetes28 Sep

Effectiveness and Safety of Fixed-Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real-World Study From China

Cohort study of 2,602 peopleType 2 diabetes

Paper

Diabetes, Obesity & Metabolism28 Sep

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

Adding a GLP-1 receptor agonist was linked to lower rates of major adverse kidney events (HR 0.70) compared with SGLT2 inhibitor monotherapy over 12 months.Adding a GLP-1 receptor agonist was linked to lower rates of major adverse kidney events (HR 0.70) compared with SGLT2 inhibitor monotherapy over 12 months.

Cohort study of 112,596 peopleKidney

Paper

Frontiers in Pharmacology23 Sep